FY2027 EPS Estimates for Nuwellis, Inc. Cut by Analyst (NASDAQ:NUWE)

Nuwellis, Inc. (NASDAQ:NUWE) – Equities research analysts at Roth Capital dropped their FY2027 earnings per share estimates for shares of Nuwellis in a research note issued on Wednesday, August 28th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $0.30 per share for the year, down from their previous forecast of $0.38. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($11.56) per share. Roth Capital also issued estimates for Nuwellis’ FY2028 earnings at $1.82 EPS.

Separately, Roth Mkm reissued a “buy” rating and set a $17.00 price objective on shares of Nuwellis in a research report on Tuesday, August 13th.

Nuwellis Trading Up 5.2 %

NASDAQ NUWE opened at $1.42 on Friday. Nuwellis has a 12 month low of $1.17 and a 12 month high of $92.75. The stock’s fifty day moving average price is $3.21 and its 200-day moving average price is $9.10. The stock has a market cap of $1.96 million, a P/E ratio of 0.00 and a beta of 0.44.

About Nuwellis

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.